Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 4;11(1):54.
doi: 10.1186/s13023-016-0441-z.

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant

Malte Lenders  1 , Frank Weidemann  2   3 , Christine Kurschat  4 , Sima Canaan-Kühl  5 , Thomas Duning  6 , Jörg Stypmann  7 , Boris Schmitz  8 , Stefanie Reiermann  1 , Johannes Krämer  2   9 , Daniela Blaschke  10 , Christoph Wanner  2 , Stefan-Martin Brand  8 , Eva Brand  11
Affiliations

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant

Malte Lenders et al. Orphanet J Rare Dis. .

Abstract

Background: Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma.

Methods: To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations.

Results: p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with significant residual GLA activity (~50 % of reference), which was associated with normal lyso-Gb3 levels. Additionally, p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T patients with stroke/transient ischemic attacks was observed.

Conclusions: We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or chaperone treatment should not be an unreflected option.

Keywords: Fabry disease; GLA mutation; Genotype; Late-onset; Lyso-Gb3; Stroke; Variant of unknown significance.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Magnetic resonance (MR) images of p.A143T patients with cerebrovascular events. a Axial MRI of the index female patient (30 years of age) suffering from an embolic stroke within the vascular territory of the right middle cerebral artery. b Coronal FLAIR-MRI of a male patient (38 years of age) suffering from an embolic stroke within the vascular territory of the left middle cerebral artery. c FLAIR-MR of a female patient (46 years of age) with TIAs and periventricular and subcortical microangiopathic and lacunar ischemic lesions (white arrow). FLAIR: fluid attenuated inversion recovery. TIA: transient ischemic attack
Fig. 2
Fig. 2
a Distribution of residual GLA activities in patients with p.A143T and Fabry disease patients with other missense GLA mutations. b Correlation of residual GLA activities with lyso-Gb3 levels in male Fabry disease patients with other missense GLA mutations and c in male patients with p.A143T. The dotted line represents the upper reference value of measured lyso-Gb3 (0.9 ng/ml). Values are given as medians with 5–95 % confidence intervals
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–1435. doi: 10.1016/S0140-6736(08)61589-5. - DOI - PubMed
    1. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236–242. doi: 10.1111/j.1365-2362.2004.01309.x. - DOI - PubMed
    1. Niemann M, Rolfs A, Störk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7:8–16. doi: 10.1161/CIRCGENETICS.113.000249. - DOI - PubMed
    1. Oliveira JP, Ferreira S, Reguenga C, Carvalho F, Månsson JE. The g.1170C > T polymorphism of the 5’ untranslated region of the human alpha-galactosidase gene is associated with decreased enzyme expression--evidence from a family study. J Inherit Metab Dis. 2008;31:S405–S413. doi: 10.1007/s10545-008-0972-0. - DOI - PubMed
    1. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802:741–748. doi: 10.1016/j.bbadis.2010.05.003. - DOI - PubMed

Substances

LinkOut - more resources